OCT2 polymorphisms and in-vivo renal functional consequence: Studies with metformin and cimetidine

Pharmacogenetics and Genomics

Volumn 18, Issue 7, 2008, Pages 637-645

  Wang, Zhi Jun ^a   Yin, Ophelia Q P ^a,c   Tomlinson, Brian ^b   Chow, Moses S S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Cimetidine; Genotype phenotype relationship; Metformin; Organic cation transporter 2 polymorphism

Indexed keywords

CIMETIDINE; GENOMIC DNA; METFORMIN; OCTAMER TRANSCRIPTION FACTOR 2; ANTIDIABETIC AGENT; ORGANIC CATION TRANSPORTER; SLC22A2 PROTEIN, HUMAN;

ADULT; ARTICLE; CHINESE; CLINICAL EVALUATION; CONCENTRATION RESPONSE; EXON; FEMALE; GENE; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN EXPERIMENT; IN VIVO STUDY; INTRON; KIDNEY CLEARANCE; KIDNEY FUNCTION; MALE; NORMAL HUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE DRUG DOSE; CHINA; DRUG ANTAGONISM; DRUG EFFECT; DRUG INTERACTION; GENETICS; KIDNEY; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; CHINA; CIMETIDINE; DNA MUTATIONAL ANALYSIS; DRUG INTERACTIONS; GENE FREQUENCY; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; METABOLIC CLEARANCE RATE; METFORMIN; ORGANIC CATION TRANSPORT PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 53049095113     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328302cd41     Document Type: Article

References (34)

1. Jonker JW, Wagenaar E, van Eijl S, Schinkel AH. Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol 2003; 23: 7902-7908.
2. Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol 2002; 13:866-974.
3. Lee W, Kim RB. Transporters and renal drug elimination. Annu Rev Pharmacol Toxicol 2004; 44:137-166.
4. Gerhard B, Natascha AW. Structure of renal organic anion and cation transporters. Am J Physiol Renal Physiol 2002; 278:F853-F866.
5. Leabman MK, Huang CC, Kawamoto M, Johns SJ, Stryke D, Ferrin TE, et al. Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 2002; 12:395-405.
6. Fukushima-Uesaka H, Maekawa K, Ozawa S, Komamura K, Ueno K, Shibakawa M, et al. Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab Pharmacokinet 2004; 19:239-244.
7. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet 1996; 30:359-371.
8. Dresser MJ, Xiao G, Leabman MK, Gray AT, Giacomini KM. Interactions of n-tetraalkylammonium compounds and biguanides with a human renal organic cation transporter (hOCT2). Pharm Res 2002; 22:562-567.
9. Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, et al. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet 2005; 20:379-386.
10. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F. Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 1987; 23:545-551.
11. Cheng CL, Chou CH. Determination of metformin in human plasma by high-performance liquid chromatography with spectrophotometric detection. J Chromatogr 2001; 762:51-58.
12. Zendelovska D, Stafilov T. Development of an HPLC method for the determination of ranitidine and cimetidine in human plasma following SPE. J Pharm Biomed Anal 2003; 33:165-173.
13. Niu T, Qin ZS, Xu X, Liu JS. Bayesian haplotype inference for multiple linked single nucleotide polymorphisms. Am J Hum Genet 2002; 70:157-169.
14. Tajima F. Statistical method for testing the neutral mutation hypothesis by DNA polymorphism. Genetics 1989; 123:585-595.
15. Li WH. Molecular evolution. Sinauer Associates, Sunderland, MA, USA; 1997.
16. Tucker GT, Casey C, Phillips PJ, Connor H,Ward JD,Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol 1981; 12:235-246.
17. Product Information: Glucophage (R), metformin hydrochloride. Bristol-Myers Squibb Company, June 2006.
18. Yin OQP, Tomlinson B, Chow MSS. Variability in renal clearance of substrates for renal transporters in Chinese subjects. J Clin Pharmacol 2006; 46:157-163.
19. Barendt WM, Wright SH. The human organic cation transporter (hOCT2) recognizes the degree of substrate ionization. J Biol Chem 2002; 277:22491-22496.
20. Pietig G, Mehrens T, Hirsch JR, Cetinkaya I, Piechota H, Schlatter E. Properties and regulation of organic cation transport in freshly isolated human proximal tubules. J Biol Chem 2001; 276:33741-33746.
21. Biermann J, Lang D, Gorboulev V, Koepsell H, Sindic A, Schroter R, et al. Characterization of regulatory mechanisms and states of human organic cation transporter 2. Am J Physiol Cell Physiol 2006; 290:C1521-C1531.
22. Urban TJ, Sebro R, Hurowitz EH, Leabman MK, Badagnani I, Lagpacan LL, et al. Functional genomics of membrane transporters in human populations. Genome Res 2006; 16:223-230.
23. Kerb R, Brinkmann U, Chatskaia N, Gorbunov D, Mornhinweg E, Keil A, et al. Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 2002; 12:591-595.
24. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117:1422-1431.
25. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol 1979; 16:195-202.
26. Sirtori CR, Pasik C. Re-evaluation of a biguanide, metformin: mechanism of action and tolerability. Pharm Res 1994; 30:187-228.
27. Hayer-Zillgen M, Bruss M, Bonisch H. Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol 2002; 136:829-836.
28. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J Pharmacol Exp Ther 2002; 302:510-515.
29. Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol 2006; 17:2127-2135.
30. Omote H, Hiasa M, Matsumoto T, Otsuka M, Moriyama Y. The MATE proteins as fundamental transporters of metabolic and xenobiotic organic cations. Trends Pharmacol Sci 2006; 27:587-593.
31. Burckhardt BC, Brai S,Wallis S, KrickW,Wolff NA, Burckhardt G. Transport of cimetidine by flounder and human renal organic anion transporter 1. Am J Physiol-Renal Physiol 2003; 284:F503-F509.
32. Cha SH, Sekine T, Fukushima JI, Kanai Y, Kobayashi Y, Goya T, Endou H. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Molr Pharmacol 2001; 59:1277-1286.
33. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.
34. Setter SM, Iltz JL, Thams J, Campbell RK. Metformin hydrochloride in the treatment of type 2 diabetes mellitus: a clinical review with a focus on dual therapy. Clin Ther 2003; 25:2991-3026.